Máj- és epeúti rák: vizsgálatok itt: Kína
619 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- No phaseTaking peopleAdjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
- Where
- Nanning
- Életkor
- 18 év to 75 év
- People
- 10 000
- Run by
- Guangxi Medical University
See details and how to joinNCT05221398 - 1. fázisNot yet taking people in KínaPhase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
- Where
- Nanjing, Shanghai
- Életkor
- 18 év to 75 év
- People
- 70
- Run by
- Acepodia Biotech, Inc.
See details and how to joinNCT07861425 - 2. fázisTaking peopleA Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 38
- Run by
- Haitao Zhao, MD
See details and how to joinNCT07850791 - No phaseTaking peopleSurgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Where
- Chengdu
- Életkor
- 18 év to 80 év
- People
- 100
- Run by
- West China Hospital
See details and how to joinNCT07410715 - 2. fázisTaking peopleA Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 87
- Run by
- Haitao Zhao, MD
See details and how to joinNCT07854600 - No phaseTaking peopleIndividualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 270
- Run by
- Nanjing Tianyinshan Hospital
See details and how to joinNCT06893887 - 2. fázisNot yet taking people in KínaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Changsha, Chengdu
- Életkor
- 18 év and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - 2. fázisTaking peopleA Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 37
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06423170 - Korai 1. fázisNot yet taking people in KínaNK521 in the Treatment of Advanced Solid Tumors
- Where
- Hefei
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- Base Therapeutics (Shanghai) Co., Ltd.
See details and how to joinNCT07657416 - No phaseTaking peopleInstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 40
- Run by
- Beijing Municipal Administration of Hospitals
See details and how to joinNCT07848750 - No phaseTaking peopleA Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
- Where
- Guangdong
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Jie Yuan,MD
See details and how to joinNCT07850882 - 2. fázisNot yet taking people in KínaCryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 56
- Run by
- Fudan University
See details and how to joinNCT07846267 - 3. fázisTaking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Kunming, Lishui, Luoyang, Nanchang, Nanning, Shandong, Shanghai, Shenyang, Weifang, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00 - 3. fázisTaking peopleA Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
- Where
- Hefei
- Életkor
- 18 év and over
- People
- 590
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06618664 - 2. fázisTaking peopleHAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou, Lanzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 76
- Run by
- Sun Yat-sen University
See details and how to joinNCT06737913 - 2. fázisTaking peopleHAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Lianghe Lu
See details and how to joinNCT07841574 - No phaseTaking peopleMultimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
- Where
- Wuhan
- Életkor
- 18 év to 80 év
- People
- 400
- Run by
- Tongji Hospital
See details and how to joinNCT07838415 - No phaseTaking peopleBiomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 500
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07840092 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseNot yet taking people in KínaTACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
- Where
- Nanjing
- Életkor
- 16 év and over
- People
- 596
- Run by
- Zhongda Hospital
See details and how to joinNCT07836309 - 1. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Where
- Guangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 232 worldwide
- Run by
- AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00 - 2. fázisTaking peopleA Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Virogin Biotech Ltd.
See details and how to joinNCT07522476 - No phaseNot yet taking people in KínaMultimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
- Where
- Aksu, Hangzhou, Jiaxing, Kaifeng, Nanchang, Taizhou
- Életkor
- 18 év to 80 év
- People
- 166
- Run by
- Zhejiang University
See details and how to joinNCT07596134 - 2. fázisTaking peopleLenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 32
- Run by
- Shunda Du
See details and how to joinNCT07639138 - 2. fázisTaking peopleOral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
- Where
- Hefei
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07793695